biostudies-literatureKwon BEMinistry of HealthNational Research Foundation of Korea2542https://www.ebi.ac.uk/biostudies/studies/S-EPMC6830241biostudies-literatureUnknown10Early secretory antigenic target-6 (ESAT6) is a potent immunogenic antigen expressed in <i>Mycobacterium tuberculosis</i> as well as in some non-tuberculous mycobacteria (NTM), such as <i>M. kansasii</i>. <i>M. kansasii</i> is one of the most clinically relevant species of NTM that causes mycobacterial lung disease, which is clinically indistinguishable from tuberculosis. In the current study, we designed a novel cell-based vaccine using B cells that were transduced with vaccinia virus expressing ESAT6 (vacESAT6), and presenting α-galactosylceramide (αGC), a ligand of invariant NKT cells. We found that B cells loaded with αGC had increased levels of CD80 and CD86 after <i>in vitro</i> stimulation with NKT cells. Immunization of mice with B/αGC/vacESAT6 induced CD4⁺ T cells produFrontiers in immunologyB Cell-Based Vaccine Transduced With ESAT6-Expressing Vaccinia Virus and Presenting α-Galactosylceramide Is a Novel Vaccine Candidate Against ESAT6-Expressing Mycobacterial Diseases.PMC6830241NRF-2017M3A9C8060390NRF-2017R1A2B2001963Ahn JHJeong HKwon BEShin SJChang SYPark EKJeong HSKo HJYeo SGShin ELee HJJung YJYoo JSfalseB Cell-Based Vaccine Transduced With ESAT6-Expressing Vaccinia Virus and Presenting α-Galactosylceramide Is a Novel Vaccine Candidate Against ESAT6-Expressing Mycobacterial Diseases.Early secretory antigenic target-6 (ESAT6) is a potent immunogenic antigen expressed in <i>Mycobacterium tuberculosis</i> as well as in some non-tuberculous mycobacteria (NTM), such as <i>M. kansasii</i>. <i>M. kansasii</i> is one of the most clinically relevant species of NTM that causes mycobacterial lung disease, which is clinically indistinguishable from tuberculosis. In the current study, we designed a novel cell-based vaccine using B cells that were transduced with vaccinia virus expressing ESAT6 (vacESAT6), and presenting α-galactosylceramide (αGC), a ligand of invariant NKT cells. We found that B cells loaded with αGC had increased levels of CD80 and CD86 after <i>in vitro</i> stimulation with NKT cells. Immunization of mice with B/αGC/vacESAT6 induced CD4⁺ T cells produ2019-01-01T00:00:00Z20192025-06-01T12:39:17.896Z2025-06-01T12:39:17.896ZS-EPMC68302413173696510.3389/fimmu.2019.02542